Astellas Pharma's Chief Financial Officer (CFO) Naoki Okamura speaks during a news conference at its headquarters in Tokyo, Japan, December 3, 2019. REUTERS
TOKYO: Japan’s Astellas Pharma Inc is buying US drugmaker Audentes Therapeutics Inc for about US$3bil in cash, in a high-priced push to make genetic medicines a key area of growth.
Gene therapies are one of the hottest areas of drug research and Astellas, Japan’s second-largest drugmaker by sales, is offering US$60 per share for San Francisco-based Audentes, a 110% premium to its closing price on Monday.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
